Literature DB >> 17068899

[Midazolam (dormicump)--clinical practice guidelines].

Predrag Stevanović1.   

Abstract

INTRODUCTION: Three benzodiazepines are available for IV injection and are commonly used in anesthesia practice: diazepam, lorazepam, and midazolam. The last is the most frequently used in anaesthesia practice. Benzodiazepines induce amnesia and sedation secondary to potentiation of the inhibitory neurotransmitter gamma amino-butyric acid (GABA). Although sleep inducing doses of midazolam (0,2-0,4 mg/kg) may produce unconsciousness in one to three minutes it is commonly used for sedation and to ensure amnesia and premedication. The effects of midazolam on the cardiovascular system are minimal. Mild decreases in blood pressure and heart rate are indicative of its sedative effect. There have been reports of respiratory depression with diazepam, however this response is dose dependent and can be marked if concomitant doses of narcotics are used. Because of its potential for depressing respiration, especially if given with narcotics, the respiratory response of these patients needs to be monitored Intravenous midazolam should be titrated to effect and the benzodiazepine antagonist flumazenil should be immediately available.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068899     DOI: 10.2298/mpns0602089s

Source DB:  PubMed          Journal:  Med Pregl        ISSN: 0025-8105


  2 in total

1.  Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.

Authors:  Ahmed Elsayem; Eardie Curry Iii; Jeanette Boohene; Mark F Munsell; Bianca Calderon; Frank Hung; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2008-05-07       Impact factor: 3.603

2.  Functional and morphological effects of diazepam and midazolam on tumor vasculature in the 9L gliosarcoma brain tumor model using dynamic susceptibility contrast MRI: a comparative study.

Authors:  Nuo Yan; Yuzhen Zheng; Cheng Yang
Journal:  Drug Des Devel Ther       Date:  2017-10-04       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.